FrancophonIA/ELRC3.0 huggingface dataset:
English: • If you are allergic to crizotinib or any of the other ingredients of this medicine (listed in Section 6, “What XALKORI contains”).
Croatian: • ako ste alergični na krizotinib ili neki drugi sastojak ovog lijeka (naveden u dijelu 6.
English: • Abnormalities in liver blood tests.
Croatian: • odstupanja u rezultatima krvnih testova jetrene funkcije.
English: Grapefruit or grapefruit juice should be avoided since it may increase crizotinib plasma concentration; St. John's wort should be avoided since it may decrease crizotinib plasma concentration (see section 4.5).
Croatian: Treba izbjegavati grejp i sok od grejpa jer mogu povećati koncentracije krizotiniba u plazmi; treba izbjegavati uzimanje gospine trave jer ona može sniziti koncentracije krizotiniba u plazmi (vidjeti dio 4.5).
English: c. Leukopenia (Leukopenia, White blood cell count decreased).
Croatian: c. Leukopenija (leukopenija, smanjeni broj leukocita).
English: One hundred seventy-three (173) patients were randomised to crizotinib and 174 patients were randomised to chemotherapy (either pemetrexed or docetaxel).
Croatian: Sto sedamdeset tri (173) bolesnika bilo je randomizirano u skupinu krizotiniba i 174 bolesnika u kemoterapijsku skupinu (pemetreksed ili docetaksel).
English: • Phenytoin, carbamazepine or phenobarbital, anti-epileptics used to treat seizures or fits.
Croatian: • fenitoin, karbamazepin ili fenobarbital - antiepileptici koji se koriste za liječenje konvulzija ili epileptičkih napadaja.
English: Therefore, starting dose adjustment is not required when crizotinib is coadministered with agents that increase gastric pH (such as proton-pump inhibitors, H2 blockers, or antacids).
Croatian: Stoga nije potrebno prilagođavati početnu dozu kod istodobne primjene krizotiniba s lijekovima koji povisuju želučani pH (poput inhibitora protonske pumpe, H2 blokatora, ili antacida).
English: Drug-induced ILD/pneumonitis should be considered in the differential diagnosis of patients with ILD-like conditions such as: pneumonitis, radiation pneumonitis, hypersensitivity pneumonitis, interstitial pneumonitis, pulmonary fibrosis, acute respiratory distress syndrome (ARDS), alveolitis, lung infiltration, pneumonia, pulmonary oedema, chronic obstructive pulmonary disease, pleural effusion, aspiration pneumonia, bronchitis, obliterative bronchiolitis, and bronchiectasis.
Croatian: Treba voditi računa o IBP-u/pneumonitisu izazvanim lijekom pri razmatranju diferencijalne dijagnoze u bolesnika sa stanjima sličnima IBP-u kao što su: pneumonitis, radijacijski pneumonitis, alergijski pneumonitis, intersticijski pneumonitis, plućna fibroza, sindrom akutnog respiracijskog distresa (ARDS), alveolitis, infiltracija pluća, pneumonija, plućni edem, kronična opstruktivna bolest pluća, pleuralni izljev, aspiracijska pneumonija, bronhitis, obliterirajući bronhiolitis i bronhiektazije.
English: Abbreviations: CI=confidence interval; N=number of patients; NR=not reached; OS=overall survival.
Croatian: Kratice: CI=interval pouzdanosti; N=broj bolesnika; NR=nije dosegnuto; OS=ukupno preživljenje.
English: Other potential causes of ILD/pneumonitis should be excluded (see sections 4.2 and 4.4).
Croatian: Treba isključiti druge moguće uzroke IBP-a/pneumonitisa (vidjeti dijelove 4.2 i 4.4).
English: e. Vision disorder (Diplopia, Halo vision, Photophobia, Photopsia, Vision blurred, Visual acuity reduced, Visual brightness, Visual impairment, Visual perseveration, Vitreous floaters).
Croatian: e. Poremećaj vida (diplopija, halo vid, fotofobija, fotopsija, zamagljen vid, smanjena oštrina vida, svjetlina pri gledanju, oštećenje vida, vidna perseveracija, leteće mutnine u vidnom polju).
English: g. Based on the stratified Cochran-Mantel-Haenszel test (2-sided).
Croatian: Na temelju stratificiranog Cochran-Mantel-Haenszelovog testa (2-stranog).
English: You should immediately contact your doctor if you experience any of the following serious side effects (see also section 2 “What you need to know before you take XALKORI ”):
Croatian: Morate se odmah javiti svom liječniku ako nastupi bilo koja od sljedećih ozbiljnih nuspojava (pogledajte i dio 2.
English: A total of 53 ROS1-positive advanced NSCLC patients were enrolled in the study at the time of data cutoff, including 46 patients with previously treated ROS1-positive advanced NSCLC and a limited number of patients (N=7) who had no prior systemic treatment.
Croatian: Ukupno 53 bolesnika s ROS1-pozitivnim uznapredovalim NSCLC-om bilo je uključeno u ispitivanje do zaključnog datuma prikupljanja podataka uključujući 46 bolesnika s prethodno liječenim ROS1pozitivnim uznapredovalim NSCLC-om i ograničeni broj bolesnika (N=7) koji prethodno nisu primali sistemsko liječenje.
English: Avoid using crizotinib in combination with other bradycardic agents (e.g., beta-blockers, non-dihydropyridine calcium channel blockers such as verapamil and diltiazem, clonidine, digoxin) to the extent possible, due to the increased risk of symptomatic bradycardia.
Croatian: Izbjegavajte primjenu krizotiniba u kombinaciji s drugim lijekovima koji uzrokuju bradikardiju (npr. beta-blokatori, nedihidropiridinski blokatori kalcijevih kanala poput verapamila i diltiazema, klonidin, digoksin) što je više moguće, zbog povećanog rizika od simptomatske bradikardije.
English: The effect of a moderate inducer including but not limited to efavirenz or rifabutin is not clearly established therefore, their combination with crizotinib should be also avoided (see section 4.4).
Croatian: Učinak umjerenog induktora, uključujući između ostalog efavirenz ili rifabutin, nije jasno ustanovljen, stoga treba izbjegavati kombinaciju s krizotinibom (vidjeti dio 4.4).
English: Do not take XALKORI
Croatian: Nemojte uzimati XALKORI
English: Following oral single dose administration in the fasted state, crizotinib is absorbed with median time to achieve peak concentrations of 4 to 6 hours.
Croatian: Nakon peroralne primjene jedne doze natašte, krizotinib se apsorbira s medijanom vremena do postizanja vršne koncentracije od 4 do 6 sati.
English: (Cyprus Branch) Τηλ: + 357 22 817690
Croatian: Pfizer Ελλάς Α.Ε. (Cyprus Branch) Τηλ: + 357 22 817690
English: OS analysis was not adjusted for the potentially confounding effects of cross over (144 [84%] patients in the chemotherapy arm received subsequent crizotinib treatment).
Croatian: OS analiza nije prilagođena za potencijalno zbunjujuće učinke križne zamjene (144 [84%] bolesnika u skupini koja je primala kemoterapiju naknadno je liječeno krizotinibom).
English: g. Estimated using the Kaplan-Meier method.
Croatian: g. Procijenjeno Kaplan-Meierovom metodom.
English: XALKORI can be prescribed to you for the initial treatment if your disease is at an advanced stage of lung cancer.
Croatian: Liječnik Vam može propisati XALKORI kao početno liječenje ako je Vaša bolest uznapredovali rak pluća.
English: Following single doses of crizotinib, the apparent plasma terminal half-life of crizotinib was 42 hours in patients.
Croatian: Nakon primjene jedne doze krizotiniba prividan terminalni poluvijek krizotiniba u plazmi u bolesnika iznosi 42 sata.
English: All-causality, all grade, vision disorder, most commonly visual impairment, photopsia, vision blurred, and vitreous floaters, was experienced by 1084 (63%) of 1722 patients treated with crizotinib.
Croatian: Poremećaji vida svih uzroka i svih stupnjeva težine, najčešće oštećenje vida, fotopsija, zamagljen vid, i leteće mutnine u vidnom polju, javili su se kod 1084 (63 %) od 1722 bolesnika liječenih krizotinibom.
English: Neuropathyd (25%) Dysgeusia (21%)
Croatian: Poremećaji živčanog sustava neuropatija d (25%) disgeuzija (21%)
English: f. Permanently discontinue for recurrence.
Croatian: Trajno obustaviti zbog mogućnosti ponovne pojave.
English: An accurate and validated assay for either ALK or ROS1 is necessary for the selection of patients for treatment with XALKORI (see section 5.1 for information on assays used in the trials).
Croatian: Pri odabiru bolesnika za liječenje lijekom XALKORI neophodno je provesti testiranje za ALK ili ROS1 pomoću preciznog i validiranog testa (vidjeti dio 5.1 za podatke o testovima koji su korišteni u ispitivanjima).
English: Crizotinib demonstrated potent and selective growth inhibitory activity and induced apoptosis in tumour cell lines exhibiting ALK fusion events (including echinoderm microtubule-associated protein-like 4 [EML4]-ALK and nucleophosmin [NPM]-ALK), ROS1 fusion events, or exhibiting amplification of the ALK or MET gene locus.
Croatian: Krizotinib je pokazao snažno i selektivno djelovanje na inhibiciju rasta te je poticao apoptozu u tumorskim staničnim linijama koje su sadržavale ALK-inačice nastale fuzijom (uključujući echinoderm microtubule-associated protein-like 4 [EML4]-ALK i nukleofozmin [NPM]-ALK), ROS1-inačice nastale fuzijom ili koje su sadržavale amplifikacije lokusa gena za ALK ili MET.
English: e. Estimated using the Kaplan-Meier method.
Croatian: Procijenjeno Kaplan-Meierovom metodom.
English: A monitoring of the QT interval should be made in case of combinations of such medicinal products (see sections 4.2 and 4.4).
Croatian: U slučaju primjene kombinacije takvih lijekova treba kontrolirati QT-interval (vidjeti dijelove 4.2 i 4.4).
English: For patients treated with a lower dose of crizotinib than 250 mg twice daily, then follow the dose reduction guidelines provided in Tables 1 and 2 accordingly.
Croatian: U bolesnika liječenih dozama krizotiniba nižim od 250 mg dvaput na dan, potrebno je slijediti smjernice za smanjenje doze navedene u Tablicama 1 i 2.
English: N=765a
Croatian: N=765
English: Grade 2, 3 or 4 ALT or AST elevation with concurrent Grade 2, 3 or 4 total bilirubin elevation (in the absence of cholestasis or haemolysis)
Croatian: Porast vrijednosti ALT-a ili AST-a stupnja 2, 3 ili 4, uz istodobni porast vrijednosti ukupnog bilirubina stupnja 2, 3 ili 4 (bez kolestaze ili hemolize).
English: XALKORI may slow or stop the growth of lung cancer.
Croatian: XALKORI može usporiti ili zaustaviti rast raka pluća te može pomoći da se tumor smanji.
English: Each carton contains 60 hard capsules.
Croatian: Jedna kutija sadrži 60 tvrdih kapsula.
English: Withhold until recovery to Grade 1 or baseline, then resume at 250 mg once daily and escalate to 200 mg twice daily if clinically toleratedb,c
Croatian: Privremeno prekinuti do sniženja vrijednosti na stupanj ≤1 ili do početnih vrijednosti, a zatim nastaviti u dozi od 250 mg jedanput na dan i povećati do 200 mg dvaput na dan ako se klinički podnosi b,c
English: The concomitant use of crizotinib with strong CYP3A4 inhibitors or with strong and moderate CYP3A4 inducers should be avoided (see section 4.5).
Croatian: Treba izbjegavati istodobnu primjenu krizotiniba sa snažnim inhibitorima CYP3A4 ili sa snažnim ili umjerenim induktorima CYP3A4 (vidjeti dio 4.5).
English: Monitoring of patients for renal function at baseline and during therapy with crizotinib is recommended, with particular attention to those who have risk factors or previous history of renal impairment (see section 4.8).
Croatian: Preporučuje se praćenje bubrežne funkcije bolesnika na početku i tijekom terapije krizotinibom s posebnom pozornosti na one bolesnike koji imaju čimbenike rizika ili prethodnu anamnezu oštećenja funkcije bubrega (vidjeti dio 4.8).
English: Supportive care for diarrhoea and constipation should include the use of standard antidiarroheal and laxative medicinal products, respectively.
Croatian: Potporno liječenje proljeva i konstipacije treba obuhvaćati primjenu standardnih antidijaroika, odnosno laksativa.
English: Abbreviations: CI=confidence interval; HR=hazard ratio; IRR=independent radiology review; N/n=number of patients; PFS=progression-free survival; OS=overall survival.
Croatian: Kratice: CI= interval pouzdanosti; HR=omjer hazarda; IRR=neovisna radiološka procjena; N/n=broj bolesnika; PFS=preživljenje bez progresije bolesti; OS=ukupno preživljenje.
English: The antitumour efficacy of crizotinib was dose-dependent and correlated to pharmacodynamic inhibition of phosphorylation of ALK fusion proteins (including EML4-ALK and NPM-ALK) in tumours in vivo.
Croatian: Antitumorska djelotvornost krizotiniba bila je ovisna o dozi i odgovarala je farmakodinamičkoj inhibiciji fosforilacije proteina ALK-inačica nastalih fuzijom (isključujući EML4ALK i NPM-ALK) u tumorima in vivo.
English: Vomiting (51%) Diarrhoea (54%) Nausea (57%) Constipation (43%) Abdominal painj
Croatian: Poremećaji probavnog sustava povraćanje (51%) proljev (54%) mučnina (57%) konstipacija (43%) bol u abdomenuj (21%)
English: Limited information is available in patients with ALK-positive and ROS1-positive NSCLC with non-adenocarcinoma histology, including squamous cell carcinoma (SCC) (see section 5.1).
Croatian: Ograničeni su podaci o bolesnicima koji imaju ALK-pozitivan i ROS1-pozitivan NSCLC, koji po histološkom tipu nije adenokarcinom, uključujući i karcinom skvamoznih stanica (engl. squamous cell carcinoma, SCC) (vidjeti dio 5.1).
English: There were reports of fatal cases of gastrointestinal perforation during post-marketing use of crizotinib (see section 4.4).
Croatian: Bilo je izvješća o smrtnim slučajevima gastrointestinalnih perforacija tijekom uporabe krizotiniba nakon stavljanja u promet (vidjeti dio 4.4).
English: Crizotinib is a selective small-molecule inhibitor of the ALK receptor tyrosine kinase (RTK) and its oncogenic variants (i.e. ALK fusion events and selected ALK mutations).
Croatian: Krizotinib je selektivan malomolekulski inhibitor ALK receptorske tirozin kinaze (RTK) i njezinih onkogenih inačica (tj. ALK-inačica nastalih fuzijom i odabranih mutacija ALK-a).
English: Vision disordere (63%)
Croatian: Poremećaji oka poremećaj vida e (63%)
English: Therefore, clinical drug-drug interactions are unlikely to occur as a result of crizotinib-mediated inhibition of the hepatic or renal uptake of medicinal products that are substrates for these transporters.
Croatian: Stoga nisu vjerojatne kliničke interakcije s drugim lijekovima kao posljedica krizotinibom posredovane inhibicije jetrenih ili bubrežnih transportera unosa lijekova koji su njihovi supstrati.
English: In rat and dog repeat-dose toxicity studies up to 3-month duration, the primary target organ effects were related to the gastrointestinal (emesis, faecal changes, congestion), haematopoietic (bone marrow hypocellularity), cardiovascular (mixed ion channel blocker, decreased heart rate and blood pressure, increased LVEDP, QRS and PR intervals, and decreased myocardial contractility), or reproductive (testicular pachytene spermatocyte degeneration, single-cell necrosis of ovarian follicles) systems.
Croatian: U ispitivanjima toksičnosti ponovljenih doza na štakorima i psima u trajanju do 3 mjeseca, primarni učinci na ciljnim organima zabilježeni su u probavnom (povraćanje, promjene fecesa, kongestija), hematopoetskom (hipocelularnost koštane srži), kardiovaskularnom (blokada različitih ionskih kanala, usporena srčana frekvencija i snižen krvni tlak, povišen LVEDP (krajnji dijastolički tlak lijeve pretklijetke), produljen QRS- i PR-interval te smanjena kontraktilnost miokarda) i reproduktivnom sustavu (pahitenska degeneracija spermatocita u testisima, nekroza pojedinačnih stanica folikula u jajnicima).
English: NR (45.8, NR)
Croatian: ND (45,8; ND)
English: Complete blood counts including differential white blood cell counts should be monitored as clinically indicated, with more frequent repeat testing if Grade 3 or 4 abnormalities are observed, or if fever or infection occurs (see section 4.2).
Croatian: Potrebno je kontrolirati kompletnu krvnu sliku, uključujući i diferencijalni broj bijelih krvnih stanica, sukladno kliničkoj indikaciji, a pretrage treba češće ponavljati ako se uoče odstupanja stupnja 3 ili 4 ili ako nastupi vrućica ili infekcija (vidjeti dio 4.2).
English: Carcinogenicity studies with crizotinib have not been performed.
Croatian: Nisu provedena ispitivanja kancerogenosti krizotiniba.
English: Patient-reported symptoms and global QOL were collected using the EORTC QLQ-C30 and its lung cancer module (EORTC QLQ-LC13).
Croatian: Simptomi koje su prijavili bolesnici i globalna kvaliteta života prikupljeni su upitnikom EORTC QLQ-C30 i njegovim modulom za rak pluća (EORTC QLQ-LC13).
English: • Cisapride, used to treat stomach problems.
Croatian: • cisapridom - koristi se za liječenje želučanih tegoba.
English: If you have any questions about how XALKORI works or why this medicine has been prescribed for you, ask your doctor.
Croatian: Ako imate pitanja o tome kako XALKORI djeluje ili zašto
English: In vitro studies showed that crizotinib is a weak inhibitor of UGT1A1 and UGT2B7 (see section 4.5).
Croatian: In vitro ispitivanja pokazala su da je krizotinib slabi inhibitor UGT1A1 i UGT2B7 (vidjeti dio 4.5).
English: Chemotherapy N=171
Croatian: kemoterapija N=171
English: If QTc increases by greater than or equal to 60 msec from baseline but QTc is <500 msec, crizotinib should be withheld and cardiologist advice should be sought.
Croatian: Ako se QTc poveća za 60 msek ili više u odnosu na početne vrijednosti, ali je QTc < 500 msek, potrebno je privremeno prekinuti primjenu krizotiniba i potražiti savjet kardiologa.
English: Crizotinib significantly prolonged progression-free survival (PFS), the primary objective of the study, compared to chemotherapy as assessed by IRR.
Croatian: Krizotinib je značajno produžio preživljenje bez progresije bolesti (engl. progression-free survival, PFS), što je bio primarni cilj ispitivanja, u usporedbi s kemoterapijom koja je procijenjena IRR-om.
English: k. Oesophagitis (Oesophagitis, Oesophageal ulcer).
Croatian: k. Ezofagitis (ezofagitis, ezofagealni ulkus).
English: Patients with pulmonary symptoms indicative of ILD/pneumonitis should be monitored.
Croatian: Potrebno je nadzirati bolesnike s plućnim simptomima koji ukazuju na IBP/pneumonitis.
English: In clinical studies with crizotinib, events of gastrointestinal perforations were reported.
Croatian: U kliničkim ispitivanjima s krizotinibom prijavljeni su slučajevi gastrointestinalnih perforacija.
English: Patient-reported symptoms and global QOL were collected using the EORTC QLQ-C30 and its lung cancer module (EORTC QLQ-LC13) at baseline (Day 1 Cycle 1) and Day 1 of each subsequent treatment cycle.
Croatian: Simptomi koje su prijavili bolesnici i globalna kvaliteta života prikupljeni su upitnikom EORTC QLQ-C30 i njegovim modulom za rak pluća (EORTC QLQ-LC13) na početku ispitivanja (1. dan 1. ciklusa) i 1. dana svakog naknadnog ciklusa liječenja.
English: Grapefruit or grapefruit juice may also increase plasma concentrations of crizotinib and should be avoided (see sections 4.2 and 4.4).
Croatian: Grejp i sok od grejpa također mogu povećati koncentracije krizotiniba u plazmi te ih treba izbjegavati (vidjeti dijelove 4.2 i 4.4).
English: Patients randomised to chemotherapy could cross over to receive crizotinib upon RECIST-defined disease progression confirmed by independent radiology review (IRR).
Croatian: Bolesnici randomizirani u kemoterapijsku skupinu mogli su preći u skupinu krizotiniba nakon što je progresija bolesti definirana RECIST-om potvrđena neovisnom radiološkom procjenom (engl. independent radiology review, IRR).
English: The absolute bioavailability of crizotinib was determined to be 43% following the administration of a single 250 mg oral dose.
Croatian: Utvrđena je apsolutna bioraspoloživost krizotiniba od 43% nakon primjene jedne peroralne doze od 250 mg.
English: MARKETING AUTHORISATION NUMBER(S) XALKORI 200 mg hard capsules EU/1/12/793/001
Croatian: XALKORI 200 mg tvrde kapsule EU/1/12/793/001
English: After a single 250 mg dose in subjects with severe renal impairment (CLcr <30 mL/min) not requiring peritoneal dialysis or haemodialysis, crizotinib AUCinf and Cmax increased by 79% and 34%, respectively, compared to those with normal renal function.
Croatian: Nakon pojedinačne doze od 250 mg u bolesnika sa teškim oštećenjem bubrega (CLcr <30 mL/min) koje ne zahtjeva peritonealnu dijalizu ili hemodijalizu, AUCinf i Cmax je očekivano povećana 79% i 34%, u usporedbi sa bolesnicima normalne bubrežne funkcije.
English: • Efavirenz, raltegravir, used to treat HIV infection.
Croatian: • efavirenzom, raltegravirom - koriste se za liječenje infekcije HIV-om.
English: If patients have severe renal impairment not requiring peritoneal dialysis or haemodialysis, the dose of crizotinib should be adjusted (see sections 4.2 and 5.2).
Croatian: Ako bolesnici imaju teško oštećenje funkcije bubrega koje ne zahtjeva peritonealnu dijalizu ili hemodijalizu, doza krizotiniba se treba prilagoditi (vidjeti dijelove 4.2 i 5.2).
English: Patients could continue crizotinib treatment beyond the time of Response Evaluation Criteria in Solid Tumours (RECIST)-defined disease progression at the discretion of the investigator if the patient was still experiencing clinical benefit.
Croatian: Bolesnici su mogli nastaviti liječenje krizotinibom nakon vremena progresije bolesti definirane prema Kriterijima procjene odgovora kod solidnih tumora (RECIST), prema odluci ispitivača, ako je bolesnik još uvijek imao kliničku korist.
English: There were reports of fatal cases of gastrointestinal perforation during post-marketing use of crizotinib (see section 4.8).
Croatian: Bilo je izvješća o smrtnim slučajevima gastrointestinalne perforacije tijekom uporabe krizotiniba nakon stavljanja u promet (vidjeti dio 4.8).
English: The most frequent adverse reactions (≥3%, all-causality frequency) associated with dosing interruptions were neutropenia (11%), elevated transaminases (7%), vomiting (5%), and nausea (4%).
Croatian: Najčešće nuspojave (≥3%, učestalost svih uzroka) povezane s prekidom primjene lijeka bile su neutropenija (11%), povišene transaminaze (7%), povraćanje (5%) i mučnina (4%).
English: Coadministration of crizotinib with strong CYP3A inhibitors is expected to increase crizotinib plasma concentrations.
Croatian: Očekuje se da će istodobna primjena krizotiniba sa snažnim inhibitorima CYP3A povisiti koncentraciju krizotiniba u plazmi.
English: In vitro studies indicated that crizotinib is a weak inhibitor of uridine diphosphate glucuronosyltransferase (UGT)1A1 and UGT2B7.
Croatian: In vitro ispitivanja pokazuju da je krizotinib slabi inhibitor uridin difosfat glukuronoziltransferaze (UGT)1A1 i UGT2B7.
English: o. Blood creatinine increased (blood creatinine increased, creatinine renal clearance decreased).
Croatian: Povišeni kreatinin u krvi (povišeni kreatinin u krvi, smanjen bubrežni klirens kreatinina).
English: Efficacy data from Study 1007 are summarised in Table 5, and the Kaplan-Meier curves for PFS and OS are shown in Figure 3 and 4, respectively.
Croatian: Podaci o djelotvornosti u Ispitivanju 1007 navedeni su u Tablici 5, a Kaplan-Meierove krivulje PFS-a i OS-a prikazane su u Slici 3, odnosno 4.
English: Coadministration with medicinal products that are substrates of transporters
Croatian: Istodobna primjena s lijekovima koji su supstrati transportnih proteina
English: Chemotherapy N=174
Croatian: kemoterapija N=174
English: Crizotinib is also an inhibitor of the Hepatocyte Growth Factor Receptor (HGFR, c-Met) RTK, ROS1 (c-ros) and Recepteur d'Origine Nantais (RON) RTK.
Croatian: Krizotinib je također inhibitor receptorske tirozin kinaze hepatocitnog faktora rasta (engl. hepatocyte growth factor receptor, HGFR, c-Met), ROS1 (c-ros) i RON (franc.
English: One hundred forty-four (84%) patients in the chemotherapy arm received subsequent crizotinib treatment.
Croatian: Sto četrdeset i četiri (84%) bolesnika u skupini koja je primala kemoterapiju primilo je nakon toga liječenje krizotinibom.